Global X MANAGEMENT CO LLC Purchases 888 Shares of Zimmer Biomet Holdings, Inc. (ZBH)

Global X MANAGEMENT CO LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,203 shares of the medical equipment provider’s stock after buying an additional 888 shares during the period. Global X MANAGEMENT CO LLC’s holdings in Zimmer Biomet Holdings were worth $843,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. BlackRock Inc. increased its position in Zimmer Biomet Holdings by 4.1% during the 2nd quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after buying an additional 679,080 shares during the period. Vanguard Group Inc. increased its position in shares of Zimmer Biomet Holdings by 2.6% in the second quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock worth $1,718,057,000 after purchasing an additional 339,106 shares during the period. Longview Partners Guernsey LTD increased its position in shares of Zimmer Biomet Holdings by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after purchasing an additional 1,128,973 shares during the period. American Century Companies Inc. increased its position in shares of Zimmer Biomet Holdings by 8.1% in the third quarter. American Century Companies Inc. now owns 4,165,353 shares of the medical equipment provider’s stock worth $487,721,000 after purchasing an additional 311,654 shares during the period. Finally, Northern Trust Corp increased its position in shares of Zimmer Biomet Holdings by 20.2% in the second quarter. Northern Trust Corp now owns 4,010,274 shares of the medical equipment provider’s stock worth $514,919,000 after purchasing an additional 673,079 shares during the period. Hedge funds and other institutional investors own 85.44% of the company’s stock.

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at $112.24 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $98.20 and a 12 month high of $133.49. The company has a market capitalization of $22,490.71, a PE ratio of 13.77, a PEG ratio of 1.72 and a beta of 1.17. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The firm had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.83 billion. During the same period in the previous year, the business posted $1.79 earnings per share. The business’s revenue for the quarter was down .8% compared to the same quarter last year. sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.03 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Global X MANAGEMENT CO LLC Purchases 888 Shares of Zimmer Biomet Holdings, Inc. (ZBH)” was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/17/global-x-management-co-llc-purchases-888-shares-of-zimmer-biomet-holdings-inc-zbh.html.

A number of research analysts recently commented on the company. Piper Jaffray Companies restated a “buy” rating and issued a $135.00 price target on shares of Zimmer Biomet Holdings in a research report on Friday, July 28th. Oppenheimer Holdings, Inc. set a $137.00 price target on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Friday, July 28th. BMO Capital Markets raised their price target on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. BidaskClub cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and an average price target of $133.71.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply